RARECast

A podcast by RARECast - Thursdays

Thursdays

Categories:

516 Episodes

  1. Disabling Antibodies that Drive Rare, Immunological Conditions

    Published: 9/14/2023
  2. Keeping the Sentinels of the Brain Vigilant

    Published: 9/7/2023
  3. Considering the Unfinished Work in Cystic Fibrosis

    Published: 8/31/2023
  4. How to Advocate for Yourself as You Battle Cancer

    Published: 8/24/2023
  5. Targeting Neuroinflammation to Treat ALS

    Published: 8/17/2023
  6. Leveraging Community Partnerships to Address a Rare Disease Behind a Medical Mystery in New Mexico

    Published: 8/10/2023
  7. Accelerating Gene Editing Therapies for Rare, Neurological Conditions

    Published: 8/3/2023
  8. Inhibiting Electrical Activity in Rare, Seizure Disorders

    Published: 7/27/2023
  9. Improving the Function and Usability of Clothing for People with Disabilities

    Published: 7/20/2023
  10. Treating Cardiopulmonary Disease with Inhaled Targeted Therapies

    Published: 7/13/2023
  11. An Ally for the Undiagnosed Emerges

    Published: 6/29/2023
  12. A Patient-Driven Registry Focused on Health-Related Quality of Life Data

    Published: 6/29/2023
  13. Help for Rare Disease Patients That’s Just a Click Away

    Published: 6/22/2023
  14. Diagnosing Autism with a Single Strand of Hair

    Published: 6/15/2023
  15. Bringing Regenerative Medicine to a Rare Bone Condition in Children

    Published: 6/8/2023
  16. Bringing Precision to CRISPR-Based Genome Editing

    Published: 6/1/2023
  17. Capturing Patients’ Experience in Their Daily Lives

    Published: 5/25/2023
  18. From One to Many

    Published: 5/18/2023
  19. A Nasal Spray to Curb Excessive Eating in Prader-Willi

    Published: 5/11/2023
  20. How One Foundation Is Laying the Groundwork to Advance Treatments for an Ultra-Rare Disease

    Published: 5/4/2023

4 / 26

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.